SMARTCOUGH-C is a study that will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds.
ResApp has developed a smartphone app that works by using algorithms to analyse the sound of a patient’s cough and provide a diagnosis.
The primary endpoint of the U.S. based study will be the diagnosis of pneumonia with the secondary endpoint being diagnosis of other common childhood respiratory diseases.
These include upper respiratory tract infection, croup, bronchiolitis and asthma.
Currently, respiratory diseases are diagnosed using a combination of auscultation, imaging and laboratory tests.
An instant, accurate diagnostic test delivered via smartphones could greatly improve patient management, give greater access to healthcare and reduce costs.
Worldwide, pneumonia is the leading cause of death of children under five years of age and is the most common reason for U.S. children to be hospitalised.
ResApp is well funded with $13 million in cash as at 30 September 2016.
The company’s share price has quadrupled since the beginning of 2016, last trading at $0.405.